Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16483774rdf:typepubmed:Citationlld:pubmed
pubmed-article:16483774lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:16483774lifeskim:mentionsumls-concept:C0020924lld:lifeskim
pubmed-article:16483774lifeskim:mentionsumls-concept:C1883695lld:lifeskim
pubmed-article:16483774pubmed:issue9lld:pubmed
pubmed-article:16483774pubmed:dateCreated2006-3-20lld:pubmed
pubmed-article:16483774pubmed:abstractTextUsing previously reported opioid receptor (OR) agonist analogs 4a-c as starting points, the structure-activity relationship (SAR) for their related series has been further refined. This SAR study has led to the identification of 2,6-di-Me-Tyr (DMT) analogs 4h and 4j as the most potent OR agonist within the series. In addition, it was discovered that 4-(aminocarbonyl)-2,6-dimethyl-Phe is a reasonable bioisostere surrogate for the DMT moiety, as supported by the OR activities of compounds 4x and 4y.lld:pubmed
pubmed-article:16483774pubmed:languageenglld:pubmed
pubmed-article:16483774pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16483774pubmed:citationSubsetIMlld:pubmed
pubmed-article:16483774pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16483774pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16483774pubmed:statusMEDLINElld:pubmed
pubmed-article:16483774pubmed:monthMaylld:pubmed
pubmed-article:16483774pubmed:issn0960-894Xlld:pubmed
pubmed-article:16483774pubmed:authorpubmed-author:BiY HYHlld:pubmed
pubmed-article:16483774pubmed:authorpubmed-author:CaiChaozhongClld:pubmed
pubmed-article:16483774pubmed:authorpubmed-author:ZhangSui-PoSPlld:pubmed
pubmed-article:16483774pubmed:authorpubmed-author:BreslinHenry...lld:pubmed
pubmed-article:16483774pubmed:authorpubmed-author:MiskowskiTama...lld:pubmed
pubmed-article:16483774pubmed:authorpubmed-author:CoutinhoSanto...lld:pubmed
pubmed-article:16483774pubmed:authorpubmed-author:HornbyPamelaPlld:pubmed
pubmed-article:16483774pubmed:issnTypePrintlld:pubmed
pubmed-article:16483774pubmed:day1lld:pubmed
pubmed-article:16483774pubmed:volume16lld:pubmed
pubmed-article:16483774pubmed:ownerNLMlld:pubmed
pubmed-article:16483774pubmed:authorsCompleteYlld:pubmed
pubmed-article:16483774pubmed:pagination2505-8lld:pubmed
pubmed-article:16483774pubmed:meshHeadingpubmed-meshheading:16483774...lld:pubmed
pubmed-article:16483774pubmed:meshHeadingpubmed-meshheading:16483774...lld:pubmed
pubmed-article:16483774pubmed:meshHeadingpubmed-meshheading:16483774...lld:pubmed
pubmed-article:16483774pubmed:meshHeadingpubmed-meshheading:16483774...lld:pubmed
pubmed-article:16483774pubmed:meshHeadingpubmed-meshheading:16483774...lld:pubmed
pubmed-article:16483774pubmed:year2006lld:pubmed
pubmed-article:16483774pubmed:articleTitleIdentification of potent phenyl imidazoles as opioid receptor agonists.lld:pubmed
pubmed-article:16483774pubmed:affiliationJohnson & Johnson Pharmaceutical Research & Development, L.L.C., Welsh and McKean Roads, PO Box 776, Spring House, PA 19477-0776, USA. HBreslin@prdus.jnj.comlld:pubmed
pubmed-article:16483774pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:16483774lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16483774lld:pubmed